Targeted therapies for advanced non-small cell lung cancer
نویسندگان
چکیده
منابع مشابه
Non-small-cell lung cancer: targeted therapies
Chemotherapy: is it still enough? The major progresses in understanding cancer biology and the mechanism of oncogenesis have allowed the development of several potential molecular target drugs for cancer treatment, which are components of signaling pathways or metabolic processes contributing to the acquisition of cancer phenotype. A general better tolerability, owing to a milder toxicity profi...
متن کامل"Targeted" therapies for non-small cell lung cancer.
The epidermal growth factor receptor (EGFR) is overexpressed in the majority of non-small-cell lung cancers (NSCLCs). This presents an opportune target for new treatment strategies designed to selectively interfere with the cancer cell growth cycle. Recent investigations into the biology of the EGFR and its downstream signaling pathways have reminded us of the complexity of cancer cell communic...
متن کاملUpdate on targeted therapies for advanced non-small cell lung cancer: nivolumab in context
While the initial treatment of non-small cell lung cancer (NSCLC) usually relies on surgical resection followed by systemic cytotoxic chemotherapy and/or radiation therapy, recent advances in understanding of NSCLC biology and immunology have spurred the development of numerous targeted therapies. In particular, a class of immune modulatory drugs targeting the immune checkpoint pathways has dem...
متن کاملMulti-Targeted Therapies in Non-Small Cell Lung Cancer
E-mail: [email protected] Tel (Fax): 86-22-2352 2919 ABSTRACT Current treatment modalities provide limited improvement in the natural course of lung cancer, and prognosis remains poor. Lung cancer is a malignancy with great molecular heterogeneity. The complexity of the signaling process leading to cancer cell proliferation and to the neoplastic phenotype supports the necessity of interferi...
متن کاملTargeted therapies and immunotherapy in non-small-cell lung cancer
Non-small-cell lung cancer is still considered a difficult disease to manage because of its aggressiveness and resistance to common therapies. Chemotherapy remains the gold standard in nearly 80% of lung cancers, but clinical outcomes are discouraging, and the impact on median overall survival (OS) barely reaches 12 months. At the end of the last century, the discovery of oncogene-driven tumour...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Oncotarget
سال: 2018
ISSN: 1949-2553
DOI: 10.18632/oncotarget.26428